CDK5 promotes HCC genesis and promotes cell migration by TPX2 by 王付强
  







博  士  学  位  论  文 
 
CDK5 促进肝癌发生并调控 TPX2 介导的
肝癌细胞迁移 
CDK5 promotes HCC genesis and promotes cell migration 





专 业 名 称： 生理学 
论文提交日期： 2016 年 4 月 
论文答辩日期： 2016 年 5 月 
 
 
















              王付强
             指导教师
       尹震宇
  教授




















另外，该学位论文为（                            ）课题（组）
的研究成果，获得（               ）课题（组）经费或实验室的
































（     ）1.经厦门大学保密委员会审查核定的保密学位论文，
于   年  月  日解密，解密后适用上述授权。 







                             声明人（签名）： 


















胞周期蛋白依赖性激酶 5 (cyclin-dependent kinase 5，CDK5)是周期素依赖蛋白激
酶家族的特殊成员，近年来发现其在肿瘤发生发展中起着关键的作用。CDK5 通




步在细胞水平研究发现，CDK5 可促进细胞的增殖。而 CDK5 激酶抑制剂
roscivitine 则抑制细胞增殖，表明其促进细胞增殖的作用依赖于其激酶活性。裸
鼠皮下成瘤实验证实 CDK5 对细胞成瘤有促进作用。我们同时在 CDK5 杂合敲









时也为 tamoxifen 与 CDK5 表达相结合从而治疗肝癌提供了实验依据。 





















Hepatocellular carcinoma(HCC) is one of the most common prevalent cancer 
worldwide, especially in China. Due to the higher incidence and lethality, it has 
become one of the main diseases threatening people's health seriously. However, the 
early diagnosis and effective therapy is not satisfaction in a majority of patients with 
HCC. So it is important to improve our understanding of its molecular pathogenesis 
and identification of novel targets for advanced stage HCC.  
Cyclin-dependent kinase 5(CDK5) is a unique member of Cyclin-dependent 
kinase family. For the past few years, it has been reported that CDK5 played a key 
role in  tumorigenesis and progression. Through binding of the non-cyclin activators 
p35 or p39，Cdk5 is active and phosphorylates a series of substrates, which participate 
in cell proliferation, migration, adhesion, apoptosis and cell cycle control of tumor. 
While, little is known about the effect of CDK5 in HCC cell function and its 
mechanism is still unclear to date. We found that the expression of CDK5 was 
significantly increased in HCC tissues corresponding to adjacent non-tumor tissues, 
and the up-regulation expression of CDK5 was correlated with decreased survival rate 
of patients. We also found that CDK5 promoted cell proliferation in HCC, and its 
inhibitor roscovitine can reduce tumor cell growth, This data demonstrated that CDK5 
promotes HCC cell growth relying on its kinase activity. On the other hand, CDK5 is 
related to HCC xenograft tumor proliferation in nude mouse model. By using CDK5 
heterozygous (cdk5+/-) transgenic mice with DEN induced tumor model, we found 
that partially loss of CDK5 significantly decrease tumor incidence, tumor number and 
size compared with wild-type mice(cdk5+/+). 
Tamoxifen, which is a non-steroidal anti-estrogen drug used in breast cancer, has 
been reported as a new inhibitor of CDK5 kinase activity by abolishing the interaction 
between CDK5 with P35. We found tamoxifen treatment dramatically suppress cell 
proliferation through inhibiting CDK5 activity. We previously screened CDK5 
















and identified TPX2, which is a molecule critical for mitosis and spindle assembly, as 
a target of CDK5 in HCC. CDK5 phosphorylates TPX2 in Ser486 which contributes 
to its’ higher protein stability. We also found that TPX2 was upregulated in HCC 
tumor tissues along with increased CDK5 levels. Silence of TPX2 significantly 
abolished the HCC cell migration induced by CDK5 which suggested that, CDK5 
promoting HCC cell migration depended on TPX2. 
In a word, at the cell level, tissue level and animal level, our study first 
comprehensively demonstrated the function and underlying mechanism of active 
CDK5 in tumorigenesis and development of HCC. The kinase activity of CDK5 is 
necessary for tumor progression and migration dependent on its substrate TPX2. Our 
findings pave the way for searching potential pharmacological targets of CDK5 and 
its substrates in HCC therapy. In addition, a therapeutic value of tamoxifen was also 
presented in our study by regulating CDK5.   
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英文缩写 英文全名 中文名称 
AD Alzheimer disease 阿尔茨海默氏症 
AFP a-fetoprotein 甲胎蛋白 
Akt Protein kinase B 蛋白激酶 B 
APP Amyloid precursor protein 淀粉样前体蛋白 
ATO Arsenic trioxide 三氧化二砷 
ATP Adenosine triphosphate 腺苷三磷酸 
Aβ Amyloid-β β-淀粉样蛋白 
BSA Bovine serum albumin 牛血清白蛋白 
CAK Cyclin-dependent kinase-activating kinase CDK 活化激酶 
CDK Cyclin-dependent kinase 周期素依赖性激酶 
CHX Cycloheximide 环己酰亚胺  
CT Computerized tomography 计算机体层成像 
DLC1 Deleted in liver cancer-1 肝癌缺失基因 1 
DMEM Dulbecco’s Modified Eagle’s Medium 改良 Eagle 培养基 
DMSO Dimethyl sulfoxide 二甲亚砜 
EGF Epidermal Growth Factor 表皮生长因子 
EGFR Epidermal growth factor receptor 表皮生长因子受体 
EMT Epithelial-Mesenchymal Transition 上皮细胞-间充质转化 
ERK Extracellular regulated protein kinases 细胞外调节蛋白激酶 
FAK Focal Adhesion Kinase 局部粘着斑激酶 
FBS Fetal bovine serum 胎牛血清 
GFP Green fluorescent protein 绿色荧光蛋白 
HCC hepatocellular carcinoma 肝细胞癌 
HGF Hepatocyte growth factor 肝细胞生长因子 
IGF Insulin-like Growth Factor 胰岛素样生长因子 
JAK Janus kinase 酪氨酸激酶 
JNK c-Jun N-terminal kinase c-Jun 氨基末端激酶 
LPS Lipopolysaccharide 脂多糖 
MAPK Mitogen-activated protein kinase 丝裂原活化蛋白激酶 
MMP Matrix metalloproteinase 基质金属蛋白酶 
















MVI Microvascular invasion 微血管侵犯 
PDGF Platelet-derived growth factor 血小板衍生生长因子 
PI3K Phosphatidylinositol 3-kinase 磷脂酰肌醇-3 羟基激
pRb Phosphorylated retinoblastoma protein 磷酸化 Rb 蛋白 
SDS Sodium dodecyl sulfate 十二烷基硫酸钠 
Ser Serine 丝氨酸 
shRNA Short hairpin RNA 短发夹 RNA 
SILAC 




siRNA Small interfering RNA 小干扰 RNA 
STAT 




TACE Transcatheter arterial chemoembolization 经导管动脉化疗栓塞
Tau Microtubule-associated protein tau Tau 蛋白 
TGF Transforming Growth Factor 转化生长因子 
TMX/TAM Tamoxifen 他莫昔芬 
TPX2 Targeting protein for Xklp2 XKLP2 靶蛋白 
VEGF Vascular endothelial growth factor 血管内皮生长因子 



































100 倍[2]，而慢性 HBV 感染占所有 HCC 危险因素的 50%以上。HCV 是发生肝癌
的第二大常见病因，占所有 HCC 患者的 20%[3]。丙型肝炎肝硬化发生 HCC 的风
险是非感染者的 20 至 200 倍，其 HCC 的年发生率范围在 1.3%到 5%左右。肝硬
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